Spanakis Marios, Alon-Ellenbogen Danny, Ioannou Petros, Spernovasilis Nikolaos
Department Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.
Computational Biomedicine Laboratory, Institute of Computer Science, Foundation for Research & Technology-Hellas (FORTH), 70013 Heraklion, Greece.
Pharmacy (Basel). 2023 Aug 19;11(4):130. doi: 10.3390/pharmacy11040130.
Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term medications. Initiating an antibiotic for an acute bacterial infection constitutes a common example. Hence, appropriate knowledge and awareness of the potential DDIs of antibiotics would lead to proper adjustments, thus preventing over- or under-treatment. For example, some statins, which are the most prescribed lipid-modifying agent (LMA), can lead to clinically important drug-drug interactions (DDIs) with the concurrent administration of antibiotics, e.g., macrolides. This review discusses the clinically significant DDIs of antibiotics associated with co-administrated lipid-lowering therapy and highlights common cases where regimen modifications may or may not be necessary.
循证处方需要考虑优化药物给药的诸多方面（例如剂量、合并症、联合使用的药物等）。一个关键问题是治疗急性疾病时使用的药物可能会干扰先前开具的长期用药。针对急性细菌感染使用抗生素就是一个常见例子。因此，对抗生素潜在药物相互作用（DDI）有适当的了解和认识，将有助于进行适当调整，从而避免治疗过度或不足。例如，一些他汀类药物是最常用的调脂药物（LMA），与抗生素（如大环内酯类）同时使用时可导致具有临床意义的药物相互作用（DDI）。本综述讨论了与联合降脂治疗相关的抗生素具有临床意义的DDI，并强调了在哪些常见情况下可能需要或不需要调整治疗方案。
